Sascha A.
- Country
- Austria
- Department
- Universitaetsklinik fuer Urologie
Research Overview
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Efficacy and Safety of Durvalumab and Bacillus Calmette-Guérin in High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer: A Phase III Randomized Study
Data & Insights
Has run more than one trial at 14 of 111 partner sites.
Specializations
Urologic Oncology
The investigator specializes in the treatment of non-muscle invasive bladder cancer, with particular emphasis on cases involving FGFR gene alterations. Their research encompasses innovative therapeutic approaches for bladder cancer management.
- Bladder Cancer Therapeutics
- Intravesical Treatment Modalities
- FGFR-Targeted Therapies
This research focuses on advancing treatment options for intermediate-risk bladder cancer patients.
Molecular Oncology
The investigator's work centers on understanding genetic alterations in bladder cancer, particularly focusing on the role of FGFR pathway mutations in disease progression and treatment response.
- Genetic Profiling
- Biomarker Analysis
- Precision Medicine Approaches
Their research integrates molecular diagnostics with personalized treatment strategies.
Clinical Outcomes
The investigator evaluates therapeutic efficacy through disease-free survival metrics in bladder cancer patients, comparing various treatment modalities for optimal patient outcomes.
- Treatment Response Assessment
- Survival Analysis
- Comparative Treatment Studies
Their work aims to establish evidence-based treatment protocols in bladder cancer care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.